SUBSCRIBE
SUBSCRIBE
News   Business

Biosyntech Inc. Signs Agreement With MedQualis As BST-DermOn’TM’ And BST-InPod’TM’ Clinical Trial CRO

October 19, 2005 | 
1 min read
BIOSYNTECH (TSX Venture:BSY) is pleased to announce the appointment of MedQualis, a contract research organization (CRO) to support BioSyntech in their upcoming BST-DermOn(TM) and BST-InPod(TM) Canadian clinical trials.
Alliances
MORE ON THIS TOPIC
Pictured: Novavax/Getty Images, STR/NurPhoto
Earnings
Novavax Sales Jump 600% YoY as COVID-19 Vaccine Still in Limbo at FDA
May 8, 2025
 · 
3 min read
 · 
Heather McKenzie
Contemporary art collage. Businessman standing under heavy pressure. Working conditions. Concept of struggle, failure, success, competition, motivation, concentration, crisis, fear Copy space for ad
Cell therapy
Vor Bio Looks for Exit in Challenging Funding Environment; Lays Off 95% of Staff
May 8, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Illustration showing businessman avoiding potholes on way to goal
Job Trends
Job Market Woes: More Funding, Stability Needed for Turnaround
May 8, 2025
 · 
5 min read
 · 
Angela Gabriel
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Teva, Korro Shed Staff in Strategic Efforts
May 8, 2025
 · 
195 min read
 · 
BioSpace Editorial Staff